RST aims to establish itself as the undisputed world leader in Quantum based electronic medical technology and treatment. The cornerstone of our business includes the highest ethical standards, the most advanced technology, a tenacious clinical research program, and a strong customer focus.
Resonant Specific Technologies, Inc. (RST), is a privately held Nevada C-Corporation that was formed by a corporate merger of Sanexas International GmbH and MicroVibration Technologies, LLC. in 2013. The staff and consultant advisors of RST are made up of several prominent MD’s, DO’s and scientific PhD’s to focus on the pain, circulatory and rehabilitation sector of modern healthcare and to target non-invasive, non-pharmaceutical, quantum physics-based treatment options.
For three decades, our ardent, progressive research team members have been developing, refining, clinically testing, test-marketing and authoring scientific papers with its breakthrough electric cell signaling and quantum resonant specific induction (QSRI) technologies.
In 1995, RST-Sanexas medical devices were revamped to use quantum-based communications-level technology with both frequency modulation (FM), as well as the typical amplitude modulated (AM) electronic signals. To this day, amplitude modulation (AM) signals represents 99% of all marketed TENS type devices even though the human body operates exclusively by (FM) frequency modulated energy.
In 1996, after exhaustive clinical application data was received, a new electronic signal generating Patent was issued (UHDfg). The Patent covers this brand new advanced random, yet sequential AM/FM signal generation technique with spread spectrum frequency hopping technology.
RST-Sanexas technology is still fundamentally more advanced than any other electromedical device in use today.
“The potential long-lasting anti-inflammatory effects of some electrical currents are based on basic physical and biochemical facts listed in the text below, namely that of stimulating and signaling effective and long-lasting anti-inflammatory effects in nerve and muscle cells. The safety of electrotherapeutic treatments in general and EST in particular has been established through extensive clinical use.”
- Robert H. Odell, Jr., MD, PhD, and Richard E. Sorgnard, PhD
We’re ready to assist you and your patients in the effective treatment of pain.Email Us
RST Sanexas is a leading provider of Electric Cell Signaling Treatment systems, providing clinics and specialists with an alternative way to effectively manage pain.